Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP110737.RAGGYCrQFiQt0ks8BIWFK3o4qDlFgF7RqSpciOWVc92SM130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP110737.RAGGYCrQFiQt0ks8BIWFK3o4qDlFgF7RqSpciOWVc92SM130_provenance.
• NP110968.RAPckIt3iCBpJW3Tez_5VjOm_Z2PKE2HNNUfOF06b-zOg130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP110968.RAPckIt3iCBpJW3Tez_5VjOm_Z2PKE2HNNUfOF06b-zOg130_provenance.
• NP148892.RABKSh9HBNsNUUdgXV75SSIZJy_6qEz2yz7--CvNfhjJs130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP148892.RABKSh9HBNsNUUdgXV75SSIZJy_6qEz2yz7--CvNfhjJs130_provenance.
• NP152236.RAz3oW8ay06W-DlAuYB2jT2EU14AyD8scfowLPwY1dL_A130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP152236.RAz3oW8ay06W-DlAuYB2jT2EU14AyD8scfowLPwY1dL_A130_provenance.
• NP69448.RAbjOdubMXXmpKVQun2kSFMKh5IVV6DNJanPpdKiKotLk130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP69448.RAbjOdubMXXmpKVQun2kSFMKh5IVV6DNJanPpdKiKotLk130_provenance.
• NP69454.RAbwmtUs85fab3l6aWlLuQ0KWvWh-tz56SHwu7--sPYr8130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP69454.RAbwmtUs85fab3l6aWlLuQ0KWvWh-tz56SHwu7--sPYr8130_provenance.
• NP212527.RAaAEPaXMxXQVerMI2ZCRo8F0PVeqmvECFNgsL-MTdDo0130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212527.RAaAEPaXMxXQVerMI2ZCRo8F0PVeqmvECFNgsL-MTdDo0130_provenance.
• NP212529.RAXnR-Im0bqgbTmcuKFdXZLku3-ekQQ6yeCAxROguvzp8130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212529.RAXnR-Im0bqgbTmcuKFdXZLku3-ekQQ6yeCAxROguvzp8130_provenance.
• NP173949.RArv_Xr66jwTVS57x3NlgSQfv2F0gTr6hZe6SjUET6f2Y130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173949.RArv_Xr66jwTVS57x3NlgSQfv2F0gTr6hZe6SjUET6f2Y130_provenance.
• NP174180.RAv2MQTRYv5wwvtUKjDy9wNg63wVwY0zdu7FCnyFO0eWw130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP174180.RAv2MQTRYv5wwvtUKjDy9wNg63wVwY0zdu7FCnyFO0eWw130_provenance.
• NP863497.RAHx26XVnUACgTW3l3Eh4dPATzGpacF6_-K_ciuIVpaeU130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP863497.RAHx26XVnUACgTW3l3Eh4dPATzGpacF6_-K_ciuIVpaeU130_provenance.
• NP215348.RAmtsSUhmuPakvffVXMbQZtLwnLQ2y-pTQsfZMIYvpS4k130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215348.RAmtsSUhmuPakvffVXMbQZtLwnLQ2y-pTQsfZMIYvpS4k130_provenance.
• NP508948.RAfxqwp8YaMl4MvjwqtmW5s9Eozyqs1cukeSW6YPr8b9s130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP508948.RAfxqwp8YaMl4MvjwqtmW5s9Eozyqs1cukeSW6YPr8b9s130_provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP69456.RA_-lmvESvP7S6O3DDG5yyQY1R2mBxphlr3snWlDF6Nu0130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP69456.RA_-lmvESvP7S6O3DDG5yyQY1R2mBxphlr3snWlDF6Nu0130_provenance.
• NP212526.RAo5feyqhvsJ9O347hdOrBj7V1A4pcGH-q65b19ioOKTk130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212526.RAo5feyqhvsJ9O347hdOrBj7V1A4pcGH-q65b19ioOKTk130_provenance.
• NP212528.RAjQso0UzJD5yEIcmHROOWnUXEnWhGZap2J6qwmz6RcSk130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212528.RAjQso0UzJD5yEIcmHROOWnUXEnWhGZap2J6qwmz6RcSk130_provenance.
• NP94927.RAkC3q0nTv8SXn66_FF-j9GG2dpAN9IyGnWqRxmZTpqcc130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP94927.RAkC3q0nTv8SXn66_FF-j9GG2dpAN9IyGnWqRxmZTpqcc130_provenance.
• NP212017.RAIezLrr1t3Vr7X_whmB7gO6LUsaQefhsvK04brVoD1jE130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212017.RAIezLrr1t3Vr7X_whmB7gO6LUsaQefhsvK04brVoD1jE130_provenance.
• NP967247.RAF4YwSokoOAd9xQ0l2vNyG1OIBeO6cG4uEzXtkAR3BhE130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP967247.RAF4YwSokoOAd9xQ0l2vNyG1OIBeO6cG4uEzXtkAR3BhE130_provenance.
• NP94924.RAGaaYfWwuUiTFuAvXgCSEkwuLQrZyF97s4iJhYrmXRb4130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP94924.RAGaaYfWwuUiTFuAvXgCSEkwuLQrZyF97s4iJhYrmXRb4130_provenance.
• NP212530.RAHnTzYdjCHeRoyKswP2AYrRuCBwGVlzqX8NjORZO21rY130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212530.RAHnTzYdjCHeRoyKswP2AYrRuCBwGVlzqX8NjORZO21rY130_provenance.
• NP94926.RA_JG5cu2toxy-ZANLAQD6g_PIyIZmKKXGo87F7mb8TDc130_assertion description "[We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP94926.RA_JG5cu2toxy-ZANLAQD6g_PIyIZmKKXGo87F7mb8TDc130_provenance.